Abstract
If the organisers of this Symposium had invited our colleagues in the pharmaceutical industry to outline their concepts of efficiency, it is probable that two quite separate areas of endeavour would have emerged. In the first place, emphasis would have been made of efficiency in terms of technology, use of manpower and the production of profitable and useful by-products. In the second place, as the result of clinical trials, the persuasive Clinical Advisors would define the type of patient likely to benefit from their preparations, the correct dosage and the possibility of untoward effects. It is these broad aspects of effectiveness and safety which I wish to discuss in relation to blood transfusion, set against the fundamental question: what we are doing with our raw material at the present time and what awaits us in the future?
Publisher
Cambridge University Press (CUP)
Subject
Electrical and Electronic Engineering,Atomic and Molecular Physics, and Optics